Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 849 | 483 | 360 |
| Samples | 633 | 405 | 224 |
| Peptides | 141 | 18 | 130 |
Function
HLA-DRB5 · Major histocompatibility complex, class II, DR beta 5
HLA-DRB5 belongs to the HLA class II beta chain paralogues. This class II molecule is a heterodimer consisting of an alpha (DRA) and a beta (DRB) chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells. The beta chain is approximately 26-28 kDa and its gene contains 6 exons. Exon one encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, exon 4 encodes the transmembrane domain and exon 5 encodes the cytoplasmic tail. Within the DR molecule the beta chain contains all the polymorphisms specifying the peptide binding specificities. Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. There are multiple pseudogenes of this gene. [provided by RefSeq, Feb 2020].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000374975 | Q30154 | 849 | 141 |
Gene Properties
Recurrent Mutations
All 141 amino-acid changes on canonical ENST00000374975 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in HLA-DRB5 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in HLA-DRB5 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 8/26 31% | 0/0 0% |
| Oral Cavity Carcinoma | 10/54 19% | 0/0 0% |
| Chronic Myelogenous Leukemia | 4/25 16% | 0/0 0% |
| Glioblastoma | 14/98 14% | 0/0 0% |
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Chordoma | 1/7 14% | 1/13 8% |
| Acute Myeloid Leukemia | 7/90 8% | 0/0 0% |
| Mesothelioma | 8/62 13% | 0/165 0% |
| Ewings Sarcoma | 11/63 17% | 0/262 0% |
| Non-Small Cell Lung Carcinoma | 44/304 14% | 11/1390 1% |
| Burkitts Lymphoma | 7/32 22% | 0/196 0% |
| Rhabdomyosarcoma | 3/33 9% | 3/171 2% |
| Neuroendocrine Tumour | 18/154 12% | 2/577 0% |
| Other Solid Cancers | 14/94 15% | 28/1515 2% |
| Plasma Cell Myeloma | 9/44 20% | 0/305 0% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Non-Cancerous | 23/104 22% | 0/830 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Chondrosarcoma | 2/14 14% | 0/75 0% |
| Hodgkins Lymphoma | 3/16 19% | 0/122 0% |
| Germ Cell Tumour | 4/25 16% | 0/169 0% |
| Squamous Cell Lung Carcinoma | 10/57 18% | 7/810 1% |
| Thyroid Gland Carcinoma | 4/45 9% | 27/1592 2% |
| Bladder Carcinoma | 8/58 14% | 9/956 1% |
| Ovarian Carcinoma | 14/109 13% | 4/998 0% |
| Melanoma | 23/210 11% | 9/1899 0% |
| Osteosarcoma | 3/45 7% | 0/166 0% |
| Colorectal Carcinoma | 17/143 12% | 30/3239 1% |
| Endometrial Carcinoma | 4/42 10% | 4/612 1% |
| Pancreatic Carcinoma | 15/89 17% | 4/1611 0% |
Mutation Distribution
Where HLA-DRB5 is mutated · all tissues, split by cell line vs tissue
How many mutations in HLA-DRB5 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 849 mutations in HLA-DRB5
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|